Why the Clinuvel share price is up 150% over the past year

Clinuvel's SCENESSE drug could receive approval from the FDA in 2019.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is now up around 150% over just the past year after rising from $8.89 this time last year to $22.13 today.

Clinuvel is a global biopharmaceutical company that develops treatment for severe and genetic skin disorders that has produced a drug named SCENESSE.

It reports the drug is on the verge of approval by the US drugs regulator the FDA. According to the company the FDA is set to communicate labelling and post marketing requirements for the drug in April 2019, with July 8 2019 a potential final review date that could see the drug approved assuming the FDA's final hurdles for the drug are all cleared.

The SCENESSE drug has already been commercialised in Europe (approved in 2014) with total sales from customers hitting $10.75 million for the quarter ending September 30 2018 to produce an operating cash profit of $7.8 million. The pharmaceutical also had $44.4 million cash on hand at September quarter end to suggest its well funded for further research ahead.

Clinuvel now has a market value of more than $1 billion and the stock has been rising as it moves closer to FDA approval that could send its sales and profits soaring.

However, investors should remember FDA approval is never guaranteed, as pharmaceutical manufacturer Starpharma Ltd (ASX: SPL) recently showed, after its application for a clinical gel product approval was knocked back by the FDA.

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »